<DOC>
	<DOCNO>NCT00711555</DOCNO>
	<brief_summary>The purpose study assess effect Emend ( aprepitant ) nausea vomit associate chemotherapy . Chemotherapy commonly cause nausea vomit affect patient ' quality life attitude toward treatment . Although nausea vomit associate chemotherapy decrease due improve therapy , patient still experience side effect . Therefore , new medication need decrease amount nausea vomit patient chemotherapy . Emend ( aprepitant ) new medication use treat nausea vomit chemotherapy , study patient receive one dose chemotherapy make people sick . However , little experience medication patient receive multiple day chemotherapy cause nausea vomiting .</brief_summary>
	<brief_title>Emend Multiple-day Emetogenic Chemotherapy</brief_title>
	<detailed_description>In study lead aprepitant 's approval , subject receive one dose highly emetogenic chemotherapy . Campos et al studied subject receive first course cisplatin contain chemotherapy include cisplatin dose 70mg/m2 report aprepitant addition granisetron dexamethasone increase number subject without acute delay emesis ( p &lt; 0.01 ) . A similar study do Poli-Bigelli et al indicate add aprepitant standard antiemetic regimen increase percentage subject without emesis use rescue therapy acute phase ( 83 % 69 % ; p &lt; 0.001 ) . Adding aprepitant also increase percentage subject emesis use rescue medication delay phase ( 68 % vs. 47 % , p &lt; 0.001 ) . Although study demonstrate benefit aprepitant one day chemotherapy regimen , benefit add aprepitant current standard antiemetic therapy ( dexamethasone plus serotonin receptor antagonist ) subject receive multiple day moderately-high highly emetogenic chemotherapy examine within clinical study . We hypothesize aprepitant dexamethasone serotonin receptor antagonist day one two day finish chemotherapy decrease nausea subject receive chemotherapy regimen include multiple day treatment moderately-high highly emetogenic chemotherapy .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Emetics</mesh_term>
	<criteria>Subjects life expectancy &gt; 3 month Subjects ECOG performance score &lt; 3 Subjects access telephone followup Subjects able swallow tablet capsule Subjects previously receive aprepitant prophylaxis chemotherapy induce nausea vomiting . Subjects allergy , hypersensitivity , contraindication aprepitant , dexamethasone , prochlorperazine serotonin receptor antagonist . Subject uncontrolled diabetes concurrent illness/condition require chronic systemic steroid preexist gastrointestinal pathology . Subjects history excessive alcohol consumption . Women pregnant lactating . Subjects nausea baseline chronically use antiemetic agent ( ) . Subjects currently receive another investigational agent . Subjects take medication interact aprepitant , include follow medication : warfarin oral contraceptive tolbutamide phenytoin midazolam ketoconazole rifampin paroxetine diltiazem Subjects poor hepatic renal function define AST &gt; 3 x ULN , ALT &gt; 3 x ULN , total bilirubin &gt; 3 x ULN , alkaline phosphatase &gt; 3 x ULN serum creatinine &gt; 2 mg/dl measure within three month start chemotherapy . Subjects hepatic metastasis AST &gt; 5 x ULN , ALT &gt; 5 x ULN , total bilirubin &gt; 5 x ULN , alkaline phosphatase &gt; 5 x ULN .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>nausea</keyword>
	<keyword>vomit</keyword>
	<keyword>multiple day</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>serotonin receptor antagonist</keyword>
	<keyword>quality life</keyword>
	<keyword>therapy</keyword>
	<keyword>corticosteroid</keyword>
	<keyword>aprepitant</keyword>
	<keyword>rescue therapy</keyword>
</DOC>